An observational study in Temporomandibular Disorders (TMD), Myalgia of Mastication Muscle and Arthralgia Syndrome, sponsored by Urbano Santana Penin. Recruiting at 2 sites in Spain. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-04.
Sponsored by Urbano Santana Penin · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Temporomandibular Joint Disorders with a site in Spain — 12 open to participants now, 13 under way, none of them phase 3. Temporomandibular Joint Disorders · Spain.
Among the 40 studies in Temporomandibular Joint Disorders with a site in Spain, this one is one of 2 that started in 2026, is one of 8 observational ones, reaches primary completion later than 6 of the 12 other live ones, and was the 39th registered.
593 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.
Browse Temporomandibular Joint Disorders studies →12 of the 40 studies in Temporomandibular Joint Disorders with a site in Spain are open now. Recruiting first, the newest first:
Fundación Universidad Católica de Valencia San Vicente Mártir · Sites in Spain
Ages 18–65
Universitat de Lleida · Sites in Spain
Ages 18–75 · Healthy volunteers
OrigenKinesis fisioterapia · Sites in Spain
Ages 18–65 · Healthy volunteers
University of Alcala · Sites in Spain
Ages 18+
University of Salamanca · Sites in Spain
Ages 18–65
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 76 Temporomandibular Joint Disorders studies recruiting now, 26 (34%) set no upper age limit and 46 (61%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is above the median of 91 across 165 observational studies indexed under Temporomandibular Joint Disorders.
Median enrollment 53 across the 32 interventional studies, 115 across the 8 observational. Of the 23 that completed or were terminated, 3 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 40 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Urbano Santana Penin as lead sponsor.
Urbano Santana Penin has 1 study filed under Temporomandibular Joint Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies in Temporomandibular Joint Disorders with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06265636OrigenKinesis fisioterapiaElectrical Stimulation of the Mandibular Nerve for Pain and Function Management in Temporomandibular Disorders | 2027-01-20 |
| NCT07514208Universitat Internacional de CatalunyaPericranial and General Sensitivity in Patients With Primary Headache | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 40 studies in Temporomandibular Joint Disorders with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Chronic temporomandibular disorders (TMDs) affect the masticatory muscles, the temporomandibular joints (TMJs), and associated structures. Except in cases of trauma, their etiology remains uncertain, debated, and multifactorial. Conservative therapies-including no active intervention-often alleviate symptoms; however, approximately 3% of the population develops persistent forms associated with substantial individual suffering and significant social and economic burden.
At the Unit of Occlusion and Prosthodontics of the University of Santiago de Compostela (USC), Physiologically Oriented Occlusal Equilibration (POOE) has been used for chronic painful TMDs since 1985. POOE aims to correct unilateral mastication patterns and to establish appropriate non-working side contacts in order to protect the temporomandibular joints from mechanical overload. Singh (Cochrane, 2024) emphasized that occlusal interventions should be evaluated with long-term follow-up of at least 3-5 years.
This is a single-blind study: the evaluator remains blinded to treatment allocation during outcome assessment. The aim of this observational study is to assess the long-term effectiveness of POOE treatments for chronic TMDs from 1985 to the present. Treatment effectiveness will be confirmed if the reduction in pain achieved with POOE is statistically significant and clinically meaningful (≥1.5/10 on a 0-10 visual analog scale) compared with sham therapy at ≥3 years post-intervention relative to baseline. Additionally, effectiveness will be supported if the proportion of individuals meeting criteria for chronic TMD ("affected") is lower in the POOE-treated group than in those receiving alternative therapies.
Chronic TMDs constitute a complex syndrome that is currently understood as comprising more than 30 distinct nosological entities. The underlying cause of their pathophysiology has not been fully elucidated. Consequently, treatments are typically empirical and applied simultaneously, including pharmacotherapy, counseling, physiotherapy, occlusal splints (perhaps the most widely used), physical modalities, and other minimally invasive procedures such as arthrocentesis or arthroscopy, extending even to total TMJ replacement. None of these interventions has demonstrated superior efficacy compared with placebo or no treatment. Globally, these patients often consult multiple specialists and undergo numerous treatment modalities, with an unpredictable prognosis.
Physiologically oriented occlusal equilibration (POOE) was shown to be more effective than placebo at 6 months post-treatment. The 2024 Cochrane review indicated that assessing the efficacy of occlusal therapies requires evaluation at least 3 to 5 years after treatment. The treatments performed at USC since 1985 for chronic TMDs represent a valuable source of long-term clinical experience that may clarify whether POOE remains effective many years after treatment (from 1985 to the present), rather than only at 6 months.
Scientific Objectives To evaluate the effect of occlusal adjustment on pain intensity in patients with chronic TMDs during long-term follow-up over several years.
To disseminate the findings-whether positive, negative, or inconclusive-in peer-reviewed scientific journals.
Methods This is an observational study, as no intervention will be applied to participants. It will be open-label or single-blind (outcome assessors will be blinded to the treatment previously received, but participants will not be). The study is cross-sectional, as it will be conducted at a single time point and in a single visit. The study will consist of diagnosing any current TMDs potentially affecting individuals who were previously treated at USC for chronic TMDs. All participating individuals are familiar with the diagnostic procedures, which include extra- and intraoral examination, dynamic recording of mandibular and condylar movements, and the tests recommended in the DC/TMD criteria.
If the participant provides authorization, clinically relevant information from their medical record regarding TMD history will be used to determine the degree of improvement or deterioration relative to the pretreatment baseline.
All individuals previously treated with occlusal equilibration therapy at the University of Santiago de Compostela for chronic TMD pain who consent to undergo a follow-up diagnostic assessment will be eligible for inclusion. The subgroup that participated in the MAP clinical trial will be analyzed separately.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Occlusal equilibration to recover physiological jaw closure and alternate chewing function
Simulation (placebo) of occlusal equilibration therapy
Group differences in change in pain intensity at 10 years follow-up in respect pretreatment scores.
Differences between POOE and sham terapy groups in mean change in pain intensity at 10 years folloow-up, in respect pretreatment scores using VAS scale 0(no pain) to 10 (worst possible pain) . Greater differences indicate a better outcome.
Time frame: Pretreatment, and 10 years follow-up
Group differences in the change in maximum unassisted mouth opening
Distance between incissors during jaw opening using 0 to 60 mm TheraBite® range of motion scale™
Time frame: pretreatment, 10 years follow-up
Odds of "success" in pain reduction of POOE compared with sham therapy
"Success" was defined as a decrease in pain scores ≥ 2 points while decreases \<2 points, as well as unmodified or increased pain scores were labeled as "failure". We also carried out an additional analysis in which we focused on strong effects of the treatment. In this additional analysis, we redefined success as a decrease in pain ≥ 4 points, and any other effect as "failure". It will be adjusted for third covariables in order to remove any confounding bias.
Time frame: Pretreatmen, 10 years follow-up
Psychological distress (GSI from SCL-90-R test)
SCL-90-R. Higher scores indicate greater psychological distress. The Global Severity Index (GSI) of the SCL-90-R ranges from 0 to 4. This index represents the mean score of all 90 items, each rated on a 0-4 Likert scale (0 = not at all, 4 = extremely). Thus, GSI values can vary between 0, indicating no symptoms, and 4, indicating maximum symptom severity.
Time frame: Pretreatment, 10 years follow-up
Change in condylar path angles
Condylar path angles are meassured between the Franckfort horizontal plane and the condylar path recprdings
Time frame: Pretreatment, 10 years follow-up
Plan to share: Undecided
Start is estimated for Feb 2026; primary completion for Jun 2026, 4 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Temporomandibular Joint Disorders →